(6R)-6-[(1R,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-1,2-diol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (6R)-6-[(1R,4E,7aR)-4-[(2Z)-2-[(5S)-5-hydroxy-2-methylidenecyclohexylidene]ethylidene]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-1-yl]-2-methylheptane-1,2-diol
• 化学式: C₂₇H₄₄O₃
• 分子量: 416.6
• InChiKey: QOWCBCXATJITSI-MDQNRWAMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• [EN] SYNTHESIS OF 1 alpha -HYDROXY VITAMIN D<br/>[FR] SYNTHESE DE LA VITAMINE D 1 alpha -HYDROXY
  申请人：LUNAR CORPORATION

  公开号：WO1996002501A1

  公开（公告）日：1996-02-01

  (EN) A method for 1$g(a)-hydroxylation of vitamin D compounds using the appropriate vitamin D as the starting material. The method requires no separatory procedures prior to the actual hydroxylation step.(FR) Procédé d'1$g(a)-hydroxylation de composés de la vitamine D dans lequel on utilise la vitamine D appropriée en tant que matériau de départ. Ce procédé ne nécessite pas de procédure de séparation avant l'étape d'hydroxylation

  一种使用适当的维生素D作为起始材料进行1$g(a)-羟化的方法。该方法在实际羟化步骤之前不需要分离程序。
• Prostane derivatives, processes for their preparation and their pharmaceutical compositions
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0010360A1

  公开（公告）日：1980-04-30

  The disclosure relates to 9β-aryloxy prostane derivatives, for example 16-(3-chlorophenoxy) -11α, 15a-dihydroxy-16 -methyl-9β-phenoxy -18, 19, 20-trinor-5-cis, 13-trans-prostadienoic acid, which possess high activity as abortifacients, cervical softeners, inducers of parturition or inhibitors of gastric acid production in mammals. These properties are typical of prostaglandin analogues of the E series, but chemically the new 9β-aryloxy prostane derivatives are prostaglandin F series analogues and are therefore more stable than the E series analogues previously used for the above purposes. The new derivatives are manufactured by known analogy processes, and are formulated in conventional manner.

  本公开涉及 9β-芳氧基前列腺烷衍生物，例如 16-(3-氯苯氧基) -11α，15a-二羟基-16-甲基-9β-苯氧基-18，19，20-三去甲-5-顺式，13-反式-脯氨二烯酸，这些衍生物作为堕胎药、子宫颈软化剂、分娩诱导剂或哺乳动物胃酸分泌抑制剂具有很高的活性。这些特性是 E 系列前列腺素类似物的典型特征，但从化学角度看，新的 9β-aryloxy 前列腺素衍生物是前列腺素 F 系列类似物，因此比以前用于上述目的的 E 系列类似物更稳定。新的衍生物采用已知的类比工艺制造，并以常规方式配制。
• Heterocyclic trichloromethyl derivatives, process for their preparation and their use
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0010348A1

  公开（公告）日：1980-04-30

  The invention relates to novel heterocyclic trichloromethyl derivatives, particularly 2-trichloromethyl-substituted quinazoline, benzo (d]-[1,3] -oxazine and benzo[e]-[1,3] -oxazine derivatives, for example 1, 2-dihydro-2 -trichloromethylquinazolin -4-one. The compounds of the invention are at least as effective as prior art trichloromethyl derivatives, which reduce the production of methane during the rumen metabolism of ruminant animals, and increase the formation of propionate at the expense of acetate, and hence improve the animals' rate of growth and their efficiency of food utilisation.

  本发明涉及新型杂环三氯甲基衍生物，特别是2-三氯甲基取代的喹唑啉、苯并(d)-[1,3]-恶嗪和苯并[e]-[1,3]-恶嗪衍生物，例如1，2-二氢-2-三氯甲基喹唑啉-4-酮。本发明的化合物至少与现有技术中的三氯甲基衍生物同样有效，可减少反刍动物瘤胃代谢过程中甲烷的产生，增加丙酸盐的形成，从而提高动物的生长速度和食物利用效率。
• Verfahren zur Herstellung von Cholestenderivaten und neue Zwischenprodukte in deren Herstellung
  申请人：F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft

  公开号：EP0019059A1

  公开（公告）日：1980-11-26

  Die Erfindung betrifft ein Verfahren zur Herstellung von Cholestenderivaten, die als Zwischenprodukte bei der Herstellung von 25,26-Dihydroxycholecalciferol Verwendung finden können. Diese Cholestenderivate besitzen die allgemeine Formel worin R1 nieder-Alkoxy und R2 und R3 nieder-Alkyl oder R2 und R3 zusammen nieder-Alkylen sind, und werden durch Wittig-Reaktion hergestellt.

  本发明涉及一种胆甾烯衍生物的制备工艺，这种衍生物可用作制备 25,26-二羟基胆 钙化醇的中间体。这些胆甾烯衍生物的通式为 其中 R1 为低级烷氧基，R2 和 R3 为低级烷基或 R2 和 R3 均为低级亚烷基，通过 Wittig 反应制备。
• Composition for solid pharmaceutical preparations of active vitamins D3 and process for preparation thereof
  申请人：TEIJIN LIMITED

  公开号：EP0116755A1

  公开（公告）日：1984-08-29

  This invention is concerned with a composition for solid pharmaceutical preparations of active vitamins D3, having the remarkably improved stability of active vitamins D3. and an extremely advantageous process for the preparation thereof from the industrial viewpoint. The composition of this invention is a composition for solid pharmaceutical preparations of active vitamins D3 prepared by forming an outer layer comprising active vitamins D3 and an excipient, which is readily soluble in an organic solvent, around an inner layer comprising an excipient which is slightly soluble in an organic solvent.

  本发明涉及一种活性维生素 D3 固体药物制剂组合物，其活性维生素 D3 的稳定性显著提高。本发明的组合物是一种用于活性维生素 D3 固体药物制剂的组合物，其制备方法是在由活性维生素 D3 和赋形剂（易溶于有机溶剂）组成的外层和由微溶于有机溶剂的赋形剂组成的内层周围形成一个外层。